Innovent's OLN324 Clinical Trial Shows Significant Superiority Over Market Leader
- Clinical Trial Success: Innovent's partner Ollin reported that OLN324 demonstrated up to 60-fold higher anti-Ang2 potency in the JADE trial involving over 160 patients, establishing it as a potential first-line treatment for diabetic macular edema, which could reshape the market landscape.
- Retinal Drying Improvement: Patients treated with OLN324 4mg experienced approximately 75% greater retinal drying improvement at Week 1 compared to faricimab, indicating a significant therapeutic advantage that may lead to broader applications in ophthalmology.
- Significant Market Potential: The success of OLN324 positions it to capture a substantial share of the ~$15 billion global retinal therapeutics market, further solidifying Innovent's leadership in the biopharmaceutical sector.
- Future Development Plans: Ollin plans to present the JADE study results at the upcoming J.P. Morgan Healthcare Conference and aims to expedite OLN324 into global Phase 3 trials, reflecting strong confidence in the drug's future market prospects.
Get Free Real-Time Notifications for Any Stock
Analyst Views on 01801
About the author
<Research>HSBC Identifies Hong Kong Stocks Receiving the Most Institutional Interest (Table)
Stock Performance Overview: Various stocks including AIA, Alibaba, and BYD showed mixed performance with AIA and Alibaba experiencing gains, while SMIC saw a decline.
Short Selling Data: Significant short selling activity was noted across multiple stocks, with BYD and SHK PPT having the highest short selling ratios at 34.941% and 35.602%, respectively.
Investment Ratings: Analysts have given "Buy" ratings to several companies including Alibaba, BOC Hong Kong, and Trip.com, while AIA is rated as "Hold."
Market Insights: JPMorgan estimates Alibaba's T-Head valuation to be between US$25-62 billion, indicating that a spinoff and separate listing is unlikely this year.
Guosen Securities Reveals Top 10 HK Stocks with Highest Foreign Capital Inflows and Outflows in Q4 2025 (Table)
Top Inflows: Guosen Securities reported the top ten Hong Kong stocks with the largest foreign capital inflows in 4Q25, led by INNOVENT BIO with an inflow of HKD6.43 billion.
Top Outflows: The report also highlighted the top ten stocks with the largest foreign capital outflows, with XIAOMI-W experiencing the highest outflow of HKD50.41 billion.
Short Selling Data: The report included short selling data for each stock, indicating significant short selling activity, particularly for XIAOMI-W and HSBC HOLDINGS.
Market Trends: The report reflects ongoing trends in the Hong Kong stock market, with notable shifts in foreign investment and short selling strategies among major companies.
